Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...

There has been an explosion of treatment options in non–muscle invasive bladder cancer (NMIBC) in recent years, with even more coming down the pike. Many of these agents have demonstrated encouraging ...

Key Takeaways Technological advancements in sacral neuromodulation include MRI-conditional devices, rechargeable systems, and extended battery lifespans, enhancing patient eligibility and reducing ...

Molecular Imaging in Risk Stratification and Adjuvant Therapy Main Discussion Topics: Potential role in identifying patients appropriate for adjuvant pembrolizumab after nephrectomy Possible utility ...

Food-Drug Interactions and Absorption Considerations This segment provides crucial information about the significant impact of food on abiraterone absorption and the clinical implications for patient ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

Panelists discuss the promising results of the BOND-3 trial evaluating intravesical cretostimogene for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC), highlighting its high complete ...

Clinical Decision-Making for Abiraterone Formulations This segment explores the practical considerations urologists face when selecting appropriate abiraterone formulations for individual patients ...

Jack Andrews, MD; Eugene Cone, MD; and Akshay Sood, MD, discuss how real-world safety and efficacy data for androgen receptor inhibitors (apalutamide, darolutamide, and enzalutamide) in nonmetastatic ...

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New ...

Key Takeaways Mitomycin for intravesical solution is the first FDA-approved treatment for recurrent LG-IR-NMIBC, with availability expected by July 2025. The phase 3 ENVISION trial demonstrated a 78% ...

Preliminary data from an expansion cohort of the phase 1b STELLAR-002 trial (NCT05176483)were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. 1 ...